SELLAS Life Sciences Group (FRA:RXK3) Total Assets : €22.48 Mil (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Total Assets?

SELLAS Life Sciences Group's Total Assets for the quarter that ended in Mar. 2024 was €22.48 Mil.

During the past 12 months, SELLAS Life Sciences Group's average Total Assets Growth Rate was 15.70% per year. During the past 3 years, the average Total Assets Growth Rate was -30.00% per year. During the past 5 years, the average Total Assets Growth Rate was -23.10% per year. During the past 10 years, the average Total Assets Growth Rate was -20.10% per year.

During the past 13 years, SELLAS Life Sciences Group's highest 3-Year average Total Assets Growth Rate was 309.60%. The lowest was -77.50%. And the median was -3.75%.

Total Assets is connected with ROA %. SELLAS Life Sciences Group's annualized ROA % for the quarter that ended in Mar. 2024 was -249.83%. Total Assets is also linked to Revenue through Asset Turnover. SELLAS Life Sciences Group's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

SELLAS Life Sciences Group Total Assets Historical Data

The historical data trend for SELLAS Life Sciences Group's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Total Assets Chart

SELLAS Life Sciences Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

14.95

37.85

23.25

19.77

5.70

SELLAS Life Sciences Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															27.18	17.14	7.58	5.70	22.48

SELLAS Life Sciences Group Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

SELLAS Life Sciences Group's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-7.314	+	13.017
	=	5.70

SELLAS Life Sciences Group's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	8.909	+	13.57
	=	22.48

SELLAS Life Sciences Group (FRA:RXK3) Total Assets Explanation

Total Assets is connected with ROA %.

SELLAS Life Sciences Group's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-35.204	/	( (5.703	+	22.479)	/ 2 )
	=	-35.204	/	14.091
	=	-249.83 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

SELLAS Life Sciences Group's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (5.703	+	22.479)	/ 2 )
=	0	/	14.091
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

SELLAS Life Sciences Group Total Assets Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

SELLAS Life Sciences Group (FRA:RXK3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

SLS:USA

Address

7 Times Square, Suite 2503, New York, NY, USA, 10036

Website

https://www.sellaslifesciences.com

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group (FRA:RXK3) Headlines

No Headlines